NCT04270474Completed
Reducing Risk of Dementia Through Deprescribing
Reducing Risk of Dementia Through Deprescribing (R2D2)
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 344 (actual)
- First submitted
- 10 Feb 2020
- Start date
- 20 Jul 2020
- Primary completion date
- 29 Jul 2026
- Lead sponsor
- Indiana University
- Diseases
- Alzheimer disease
- NCT number
- NCT04270474
What you commit to
- Study type: Interventional
- Participants enrolled: 344
- From 20 Jul 2020 to the primary completion date, 29 Jul 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of schizophrenia, bipolar disorder, or schizoaffective disorder defined by International Classification of Diseases (ICD) version 9/10 codes
- Diagnosis of Alzheimer's Disease or Related Dementia as determined by (a), (b), or (c) below:
- ICD-9/10 codes, or
- Current use of a medication for Alzheimer's Disease or a Related Dementia, or
- A pattern of responses to the Functional Activities Questionnaire (FAQ) that indicate dementia (i.e., ≥ 3 FAQ items are scored at "requires assistance," or if ≥ 1 FAQ item is scored at "dependent").
Other
- Permanent resident of an extended care facility (nursing home)
Who the study is looking for
- Age 65 and older;
- At least one office visit to their primary care physician within the previous 12 months;
- Use of a target anticholinergic medication within the last two weeks OR medical record evidence of exposure to target anticholinergic medications at or above a cognitive risk threshold in the prior 12 months
- Able to communicate in English;
- Access to a telephone
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Community Health Network Foundation, Inc. Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
| Indiana University Health Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.